Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications for amifampridine tablets, 10 mg. Amifampridine tablets, 10 mg, bioequivalent to the reference listed drug (RLD), Firdapse tablets, 10 mg, of Catalyst Pharmaceuticals, Inc., for the indication in the approved labelling. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity. Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across India, the US, other developed markets, and emerging markets, with products distributed in over 100 markets. Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars, and continues to strengthen its market position through a differentiated portfolio. |